Charles Schwab Investment Management Inc. Decreases Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Charles Schwab Investment Management Inc. lowered its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 637,633 shares of the company's stock after selling 35,813 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.75% of Progyny worth $10,999,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PGNY. SBI Securities Co. Ltd. purchased a new position in Progyny in the 4th quarter valued at $74,000. Acuitas Investments LLC purchased a new position in shares of Progyny in the fourth quarter worth about $2,980,000. Baillie Gifford & Co. boosted its position in Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock worth $22,989,000 after acquiring an additional 456,853 shares during the last quarter. Entropy Technologies LP grew its stake in Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock valued at $826,000 after acquiring an additional 2,499 shares in the last quarter. Finally, Caitlin John LLC lifted its stake in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on PGNY shares. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group boosted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $24.82.

Remove Ads

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the business's stock in a transaction on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the purchase, the chairman now directly owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.30% of the stock is owned by corporate insiders.

Progyny Stock Down 2.5 %

NASDAQ:PGNY traded down $0.56 during trading hours on Tuesday, reaching $21.49. 1,035,888 shares of the stock were exchanged, compared to its average volume of 1,615,650. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $38.98. The business has a 50-day moving average of $21.96 and a two-hundred day moving average of $18.54. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 37.05, a PEG ratio of 2.39 and a beta of 1.41.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.